Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919843 | 1.00 | KDM4E (0.50) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| Formic Acid SCHEMBL29919771 | 0.91 | KDM4E (0.47) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL1043754 | 0.85 | DYRK1A (0.56) | KDM4EDYRK1AALDH1A1HSD17B10HPGD | |
| SCHEMBL627808 | 0.81 | PDPK1 (0.55) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL31032738 | 0.81 | PDPK1 (0.55) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL27805303 | 0.81 | KDR (0.47) | ALDH1A1SMN1; SMN2ITKMAPTMEN1 | |
| SCHEMBL6360732 | 0.80 | DYRK1A (0.51) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL28264393 | 0.80 | ITK (0.47) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL15792074 | 0.80 | ITK (0.47) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL6361114 | 0.80 | ITK (0.50) | KDM4EDYRK1AALDH1A1HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163189-A1 | RAFT AGENT FOR PHOTO-CONTROLLED POLYMERIZATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | SHANDONG UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117050062-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-05 | — | — | US | disclosed |
| CN-111187221-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111171000-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-111170999-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4036094-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | The Trustees of Columbia University in the City of New York (US) | 2022-08-03 | — | — | EP | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| WO-2004043933-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043932-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097575-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2004-05-20 | — | — | US | disclosed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-3988492-A | Pressure sensitive copy paper employing pyrazoloxanthene compounds | THE MEAD CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | KDM4E 3056/4885DYRK1A 4302/4885ALDH1A1 375/4885 |
| US-20250163189-A1 | RAFT AGENT FOR PHOTO-CONTROLLED POLYMERIZATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | WASF2, RFTN1, WEE2 | KDM4E 3124/4885DYRK1A 4609/4885ALDH1A1 235/4885 |
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | KDM4E 1520/4885DYRK1A 2218/4885ALDH1A1 3360/4885 |
| US-20040097575-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | KDM4E 1362/4885DYRK1A 4545/4885ALDH1A1 938/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885DYRK1A 4862/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.